Selected fourth quarter product approvals.



Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

FDA approves Juxtapid lomitapide to treat homozygous familial hypercholesterolemia (hoFH)

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)

FDA approves Adasuve Staccato loxapine to treat acute agitation in adults with schizophrenia or bipolar disorder

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

FDA approves Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant to or intolerant of prior treatment with tyrosine kinase inhibitors

AstraZeneca plc (LSE:AZN; NYSE:AZN)/Bristol-Myers Squibb Co. (NYSE:BMY)

EC approves Forxiga dapagliflozin to treat Type II diabetes

Bayer AG (Xetra:BAYN)/

EC approves Xarelto rivaroxaban to treat pulmonary embolism (PE) and to prevent

Johnson & Johnson (NYSE:JNJ)

recurrent deep vein thrombosis (DVT) and PE; FDA approves Xarelto to treat DVT or PE, and to reduce the risk of recurrent DVT and PE